Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC is a clinical-stage biopharmaceutical company dedicated to developing innovative products for diseases with high unmet medical needs. The company's mission is to advance medicines that offer a brighter future for patients with serious conditions not adequately addressed by existing treatments. Headquartered in Cardiff, United Kingdom, Biodexa focuses on leveraging its proprietary drug delivery technologies to enhance the efficacy and precision of its therapeutic candidates.

Biodexa's pipeline includes several key development programs. Its lead candidate, eRapa, is an oral tablet formulation of rapamycin (sirolimus) being prepared for a Phase 3 registration study in familial adenomatous polyposis (FAP), a rare and serious condition. eRapa is also under development for non-muscle invasive bladder cancer. Other significant programs include tolimidone, aimed at treating type 1 diabetes, and MTX110, which is being investigated for aggressive rare and orphan brain cancers such as recurrent glioblastoma and diffuse midline glioma. The company's technological foundation is built upon its Q-Sphera, MidaCore, and MidaSolve drug delivery platforms, designed to improve bioavailability, enable sustained release, and facilitate direct-to-tumor delivery.

In recent news, Biodexa Pharmaceuticals PLC announced a partnership with Syngene in April 2026 for the manufacture of MTX240 GMP clinical trial supplies. In March 2026, the company launched a global early access program for eRapa for FAP patients through a strategic partnership with Tanner Pharma Group, and also released its preliminary results for the year ended December 31, 2025. Earlier in February 2026, Biodexa licensed a Phase 1 ready drug candidate, MTX240 (formerly OPB-171775), from Otsuka for the treatment of rare stomach cancer (TKI-resistant GIST). Stephen Stamp serves as the Chief Executive Officer, and Fiona Sharp was promoted to Chief Financial Officer and Company Secretary in January 2026. The company also underwent a 1-for-5 reverse ADR split, effective around April 6, 2026.